BACKGROUND: The optimal age for administration of recently approved prophylactic human papillomavirus (HPV) vaccines remains undetermined. OBJECTIVES: The aim of the study was to explore the age-specific seroprevalence of HPV 16 and 18 in the general population to design an HPV vaccination campaign for Taiwan. STUDY DESIGN: HPV seroprevalence was assessed by virus-like particle (VLP)-based ELISA in 1702 plasma samples collected in 1999. RESULTS: The sample population consisted of 1000 (58.8%) females and 702 (41.2%) males; age ranged from 17 days to 86 years. The age-specific distributions reveal a significant rise in HPV 16 seropositivity commencing at 19-25 years of age and peaking at >60 years. The trend of seropositivity increase with age was also highly significant for HPV 18 (P(Trend)<0.0001). Males had lower overall seroprevalence in gender comparison (7.6% versus 3.85% for HPV 16, 3.9% versus 2.71% for HPV 18), were older at seroconversion (19-25 years versus 26-30 years) with a more obvious seropositivity nadir in middle age. CONCLUSION: The age-specific seroprevalence of HPV 16 and 18 increases in young adults after the age of 18 years, with gender distribution varying. We conclude that the optimal age for universal HPV vaccination in Taiwan is 15 years or below.
BACKGROUND: The optimal age for administration of recently approved prophylactic human papillomavirus (HPV) vaccines remains undetermined. OBJECTIVES: The aim of the study was to explore the age-specific seroprevalence of HPV 16 and 18 in the general population to design an HPV vaccination campaign for Taiwan. STUDY DESIGN:HPV seroprevalence was assessed by virus-like particle (VLP)-based ELISA in 1702 plasma samples collected in 1999. RESULTS: The sample population consisted of 1000 (58.8%) females and 702 (41.2%) males; age ranged from 17 days to 86 years. The age-specific distributions reveal a significant rise in HPV 16 seropositivity commencing at 19-25 years of age and peaking at >60 years. The trend of seropositivity increase with age was also highly significant for HPV 18 (P(Trend)<0.0001). Males had lower overall seroprevalence in gender comparison (7.6% versus 3.85% for HPV 16, 3.9% versus 2.71% for HPV 18), were older at seroconversion (19-25 years versus 26-30 years) with a more obvious seropositivity nadir in middle age. CONCLUSION: The age-specific seroprevalence of HPV 16 and 18 increases in young adults after the age of 18 years, with gender distribution varying. We conclude that the optimal age for universal HPV vaccination in Taiwan is 15 years or below.
Authors: Troy J Kemp; Alfonso García-Piñeres; Roni T Falk; Sylviane Poncelet; Francis Dessy; Sandra L Giannini; Ana Cecilia Rodriguez; Carolina Porras; Rolando Herrero; Allan Hildesheim; Ligia A Pinto Journal: Vaccine Date: 2008-05-19 Impact factor: 3.641
Authors: Jennifer S Smith; Adam K Lewkowitz; You-Lin Qiao; Jia Ji; Shangying Hu; Wen Chen; Rong Zhang; Kai Li Liaw; Mark Esser; Frank J Taddeo; Robert G Pretorius; Jerome L Belinson Journal: Int J Cancer Date: 2012-01-27 Impact factor: 7.396
Authors: Pang Yao; Iona Millwood; Christiana Kartsonaki; Alexander J Mentzer; Naomi Allen; Rima Jeske; Julia Butt; Yu Guo; Yiping Chen; Robin Walters; Jun Lv; Canqing Yu; Martyn Plummer; Catherine de Martel; Gary Clifford; Li-Ming Li; Tim Waterboer; Ling Yang; Zhengming Chen Journal: BMJ Open Date: 2022-05-09 Impact factor: 3.006
Authors: Jia Ji; Hai-Kui Sun; Jennifer S Smith; He Wang; Mark T Esser; Shangying Hu; Robert G Pretorius; Wen Chen; Jerome L Belinson; You-Lin Qiao Journal: BMC Infect Dis Date: 2012-06-20 Impact factor: 3.090
Authors: Anna Loenenbach; Michael Pawlita; Tim Waterboer; Thomas Harder; Christina Poethko-Müller; Michael Thamm; Raskit Lachmann; Yvonne Deleré; Ole Wichmann; Miriam Wiese-Posselt Journal: BMC Infect Dis Date: 2022-01-10 Impact factor: 3.090